31 results about "Microgram" patented technology

The invention belongs to the technical field of biological materials and biological information, and provides a space phosphorylation modification omics detection method. According to the detection method disclosed by the invention, proteomics analysis can be carried out on trace sample phosphorylation, 4259 phosphorylation sites can be identified by 5 micrograms of peptide fragments, and the credibility of 3506 sites is greater than 0.75.

The invention relates to the technical field of immunochromatography analysis, and discloses a signal enhancer of a colloidal gold immunochromatography rapid detection card and a preparation method thereof, the signal enhancer comprises a silver ion solution, a thiourea-ascorbic acid synergistic reducing agent, a pH buffer system and a surfactant stabilizing system, the signal amplification is realized by catalyzing and depositing silver nanoparticles on the surface of colloidal gold, the operation is simple and convenient, one-time addition is realized, and the reaction is completed within 5-10 minutes; the sensitivity is improved by 5-10 times, and the specificity is higher than 98%; the stability is excellent, and the storage time is 12 months at 4 DEG C; various colloidal gold rapid detection cards are universally compatible; compared with the prior art, the colloidal gold immunochromatography rapid detection card has the advantages that the cost is controllable, the single detection is increased by 0.3-0.5 yuan, and the colloidal gold immunochromatography rapid detection card is particularly suitable for ultra-sensitive detection of small molecular substances in the field of food safety, for example, the detection limit of malachite green reaches 0.1 microgram per liter, the detection limit of fipronil reaches 0.5 microgram per liter, and the application range of the colloidal gold immunochromatography rapid detection card is obviously expanded.

The invention relates to a receptor reagent and application thereof. The receptor reagent comprises a buffer solution and receptor particles suspended in the buffer solution, the receptor particles can react with active oxygen to generate chemiluminescence, and the receptor reagent is characterized in that the ZETA potential of the receptor particles is not higher than 0 mV and not lower than-15 mV; the sugar content per milligram of receptor particles is greater than 40 micrograms. The receptor reagent provided by the invention can be produced on a large scale, is low in cost, qualified in quality and stable in performance, and can meet the sensitivity requirement and the linear range requirement; the kit containing the receptor reagent has the advantages of strong sample anti-interference capability and good test performance.

The invention relates to the technical field of breeding regulation and control of black goats, in particular to a hormone treatment method for inducing estrus synchronization of black goats, which comprises the following steps: placing a CIDR vaginal suppository containing 1.38-1.56 g of progesterone into the vagina of an ewe, and keeping for 12-14 days; 48 hours before the thrombus is removed, intramuscularly injecting a sustained release preparation of 330 IU follicle-stimulating hormone and 30% polyvinylpyrrolidone; when the thrombus is removed, intramuscularly injecting a mixed solution containing 330IU pregnant mare serum gonadotropin and 0.1 mg of cloprostenol; 24 hours after the thrombus is removed, 25 micrograms of luteinizing hormone is intravenously injected to release hormone A3; single-time artificial insemination is performed within 48-56 hours after injection, 0.5 ml of semen is left for each injection, and the number of effective sperms is not less than 1.5 * 10 < 8 >. By precisely regulating and controlling CIDR progesterone and multi-hormone stepped injection, the estrus synchronization rate of a group is larger than or equal to 95%, and the traditional synchronization bottleneck is broken through; insemination parameters are controlled and optimized management is carried out, each fetal live lamb is 2.5-3.0, and the breeding efficiency is improved; treatment is started 45-50 days after delivery, the lambing interval is 210 + / -10 days, and large-scale efficient breeding is assisted.

The invention relates to application of Antarctic red in repairing skin barrier injury and delaying skin aging, and belongs to the technical field of biology, the Antarctic red has no toxicity to cells when the concentration is not higher than 250 g / mL, when the concentration of the Antarctic red is 15.63-250 g / mL, the Antarctic red can promote repair of injured cells, the maximum improvement rate is 15.44% (plt; the anti-aging performance (plt, 0.05) of human fibroblasts and human immortalized keratinocytes can be remarkably improved, the effect is superior to or equivalent to that of positive control drug nicotinamide (plt, 0.001) when the concentration is 16 micrograms / mL, and the anti-aging composition can be used for repairing skin barrier injury and delaying skin aging.

The utility model discloses a colloidal gold test paper card for rapidly determining rice yeast acid in whole blood. The colloidal gold test paper card comprises a bottom plate as well as a glass cellulose membrane, a filtration binding area, a detection area and a water absorption pad which are sequentially arranged on the bottom plate from left to right, the filtration binding area adopts an antigen-antibody binding technology, red blood cells in whole blood can be retained on a filter membrane of a sample pad without moving, other substances in the whole blood can smoothly pass through, and the detection effect is good. According to the present invention, the kit can be combined with the rice yeast acid so as to eliminate the background interference, can be combined with the rice yeast acid, and can be detected through the detection region, such that the rice yeast acid in the whole blood can be accurately detected, the accuracy and the specificity of the rice yeast acid determination in the whole blood can be effectively improved, the application range and the efficiency of the trace whole blood sample in the detection can be expanded, and the redundant pretreatment operation is not required; the method is simple in operation and rapid in detection, and can obtain a result within 15 minutes only by taking 10 microliters of trace whole blood, and the lowest detection limit of 50 micrograms / L is reached.

The invention discloses a bionic polypeptide nano-composite skin permeation carrier and a preparation method thereof. According to the carrier, a biodegradable high polymer material is used as a nano core, hydrophobic active ingredients are loaded, and a nano composite system with a bifunctional bionic shell is formed through covalent immobilization of bionic cell-penetrating peptide and biological adhesion peptide. The preparation method comprises three steps of oil / water emulsification volatilization nucleation, peptide coupling modification and freeze drying. The obtained carrier has the characteristics of actively penetrating a skin barrier and long-acting residence, the encapsulation efficiency reaches 85% or above, the steady-state transdermal rate is increased to 3.7 micrograms / cm < 3 > / h, and the drug leakage rate is lower than 7% after the carrier is stored for 30 days. By simulating the natural mechanism of skin permeation and adhesion, efficient encapsulation, steady-state release and deep delivery of active ingredients are realized, and the preparation method is suitable for the fields of transdermal drug delivery, skin repair, beauty and the like, and has good application prospects and industrialization potential.

The present application relates to the technical field of immunochromatographic analysis, and discloses a signal enhancer for a colloidal gold immunochromatographic rapid detection card and a preparation method thereof, the signal enhancer comprises a silver ion solution, a thiourea-ascorbic acid synergistic reducing agent, a pH buffer system and a surfactant stabilizing system, signal amplification is realized by catalytic deposition of silver nanoparticles on the surface of colloidal gold, the present application is simple to operate, is added at one time, and reaction is completed in 5-10 minutes; sensitivity is improved by 5-10 times, specificity is higher than 98%; stability is excellent, 12 months of storage at 4 DEG C; it is compatible with various colloidal gold rapid detection cards; cost is controllable, single detection is increased by 0.3-0.5 yuan, and the present application is especially suitable for super-sensitive detection of small molecule substances in the field of food safety, such as detection limit of malachite green of 0.1 microgram per liter, detection limit of fipronil of 0.5 microgram per liter, and the application range of the colloidal gold immunochromatographic rapid detection card is significantly expanded.

The invention provides a detection method of Ruyi golden yellow powder, and belongs to the technical field of quality control of traditional Chinese medicine preparations. According to the method, apigenin is used as a reference substance, the content of total flavonoids in Ruyi golden yellow powder in terms of apigenin is calculated by preparing a reference substance solution, establishing a standard curve and determining the absorbance of a sample to be detected by adopting ultraviolet-visible spectrophotometry, if the content of apigenin in Ruyi golden yellow powder to be detected is not lower than 20 micrograms / g, the detection is qualified, otherwise, the detection is qualified, and the content of total flavonoids in Ruyi golden yellow powder to be detected is not lower than 20 micrograms / g. Unqualified products are obtained. The method can be used for objectively, comprehensively and accurately evaluating the quality of the Ruyi golden yellow powder, and has important significance on guaranteeing the quality of the product while guaranteeing the curative effect of the product.

The invention provides a method for constructing a myositis-related interstitial lung disease mouse model, which comprises the following steps: injecting 10 micrograms of ODN2395 into the abdominal cavity of a female BALB / c mouse, injecting 0.25 mL of a mixed emulsion of SD (Sprague Dawley) rat skeletal muscle homogenate and a complete Freund's adjuvant into each of the two sides of the back of the female BALB / c mouse at the same time point, and feeding for a certain time to obtain a film-formed mouse. The method has the advantages that raw materials are easy to obtain, and the modeling method is simple; 2, the modeling time is relatively short; and 3, the model forming rate is high, and the method is more in line with the pathogenesis and pathological phenotype of IIM-ILD.

The invention relates to a fluorescence detection reagent for on-site rapid classification and identification of synthetic cannabinoid. According to the detection reagent, based on a steric hindrance engineering thermodynamic gating strategy, a fluorescent probe molecule tert-butyl (4-(2-(4-hydroxybutyl)-1, 3-dioxo-2, 3-dihydro-1H-benzo [de] isoquinoline-6-yl) phenyl) carbamate containing a specific steric hindrance group (Boc group) is designed and synthesized. And the probe forms a fluorescence quenching aggregate in a thermodynamic metastable state in a system. The aggregate constructs a specific energy threshold value, and only when the aggregate encounters synthetic cannabinoid of a high affinity category (simultaneously having a keto / ester head and a hydrophobic tail chain), dissociation of the aggregate is synergistically triggered through multiple non-covalent interaction, and a remarkable fluorescent lightening signal is generated. The response time is less than 1 s, the detection limit can reach the microgram level, and the method has the characteristics of simplicity and convenience in operation, strong anti-interference performance (no false positive), convenience in visual observation and the like. The problem that a traditional single-molecule probe is difficult to classify and identify synthetic cannabinoid in a complex matrix is solved, and powerful technical support is provided for on-site investigation of drugs.

The invention belongs to the technical field of biological materials and tissue engineering, and discloses a culture medium capable of directionally up-regulating expression of endogenous N-cadherin of hMSCs (human mesenchymal stem cells) as well as a preparation method and application of the culture medium, a fusion protein of a nerve cell cadherin extracellular domain 1-2 and an Fc segment is fixed on the surface of the medium, and the amino acid sequence of the fusion protein is shown as SEQ ID NO: 1. The problems that natural N-cadherin is short in half-life period and unstable in surface adsorption are solved through Fc segment modification. Experimental data show that the fixing efficiency of the N-cad1-2-Fc fusion protein on the surface of polystyrene is remarkably improved, the ELISA detection OD value reaches 1.2 under the concentration of 10 micrograms / mL, and the protein is uniformly distributed and cannot be lost due to physical flushing or time lapse.

The invention provides a pretreatment method for determining the content of < 14 > C in a microgram-level carbon sample by an accelerator mass spectrometer. Comprising the following steps: (1) configuring the amount of a diluted sample according to the carbon content of a trace CO2 gas sample and preparing a diluted CO2 gas sample; (2) mixing the diluted CO2 gas and the trace CO2 gas; and (3) reducing the mixed CO2 gas into a graphite sample by a zinc-iron method, determining the 14C content of the mixed sample by using an accelerator mass spectrometer, and correcting the determination result by a formula to obtain the 14C content of the trace sample. The method solves the problems that graphite is difficult to synthesize and < 14 > C analysis is difficult due to low carbon content of microgram-grade carbon samples, and develops a simple, efficient and reliable pretreatment method suitable for determining microgram-grade carbon samples with different < 14 > C contents by an accelerator mass spectrometer; the method has certain significance in promoting the application of the micro sample 14C analysis in a plurality of research fields such as geoscience, environmental science and archaeology.

The invention relates to the technical field of environmental monitoring and analysis, in particular to a detection method of environmental estrogen. According to the detection method, a recombinant human estrogen receptor GST-ER alpha-LBD is used as a biological recognition molecule, and an anti-GST antibody and a corresponding enzyme-labeled secondary antibody are used as reporter molecules; an estradiol derivative-bovine serum albumin conjugate with a proper connecting arm is coated on a microwell plate, and the equivalent concentration of environmental estrogen is detected in an indirect competition mode. The method for detecting the equivalent concentration of the environmental estrogen is accurate, reliable, sensitive, rapid, green and safe, the detection limit of the estradiol can be as low as 0.072 microgram / L, and the equivalent concentration of the environmental estrogen can be detected.

The invention discloses a method for detecting campylobacter jejuni cell swelling toxin CdtB in food, and provides application of a campylobacter jejuni cell swelling lethal toxin CdtB monoclonal antibody to detection of campylobacter jejuni in food for the first time. The invention aims to establish the detection kit and the detection method based on the campylobacter jejuni cell swelling toxin CdtB monoclonal antibody, and the detection kit and the detection method have relatively strong specificity and sensitivity. The CdtB monoclonal antibody prepared by the invention can be combined with CdtB protein secreted by campylobacter jejuni in food, so that the detection of the campylobacter jejuni is realized. The detection speed is high, semi-quantitative detection can be achieved, the detection sensitivity is high, and the lowest CdtB mass of 0.01 microgram can be detected.

The invention relates to a receptor reagent and application thereof. The receptor reagent comprises a buffer solution and receptor particles suspended in the buffer solution, the receptor particles can react with active oxygen to generate chemiluminescence, and the receptor reagent is characterized in that the ZETA potential of the receptor particles is not higher than-10 mV and not lower than-50 mV; the sugar content of each milligram of receptor particles is not higher than 25 micrograms. The receptor reagent provided by the invention can be produced on a large scale, is low in cost, qualified in quality and stable in performance, and can meet the sensitivity requirement and the linear range requirement; the kit containing the receptor reagent has the advantages of strong sample anti-interference capability and good test performance.

The invention belongs to the technical field of analytical chemistry, and discloses an analytical method for measuring the dissolution amount of HMDA in a medical instrument containing a polyurethane material, which comprises the following specific steps: step 1, preparing an extraction solution, selecting a medical instrument sample containing the polyurethane material, removing an outer package and components not in contact with a human body, and adding an extraction solvent according to a specified proportion; ethanol and other mild extraction solvents are adopted, the polyurethane material does not need to be dissolved, only HMDA in the polyurethane material is dissolved out, the problem of matrix interference caused by material dissolution in the prior art is solved, and the method is suitable for various medical instruments containing the polyurethane material; meanwhile, derivatization is not needed in sample pretreatment, sample injection detection can be directly carried out through extraction and dilution, and the steps are simple; the chromatographic analysis time is only 6 min, and the high-throughput screening requirement is met; the UPLC-MS / MS technology and optimized mass spectrum parameters are adopted, the detection limit is as low as 2.600 micrograms per liter, the quantitation limit is 5.201 micrograms per liter, the method is far superior to an existing liquid chromatography method, and the detection requirement of large-size medical instruments can be met.

The invention relates to the field of in-vitro detection. Specifically, the invention relates to a high-affinity C4 nucleic acid aptamer and application thereof. The invention provides a nucleic acid aptamer specifically combined with a complement C4 and a kit for detecting the complement C4. The nucleic acid aptamer comprises a nucleotide sequence as shown in SEQ ID NO: 127 or a functional analogue of the nucleotide sequence. Compared with an antibody, the C4 aptamer has the advantages of being high in targeting specificity, high in stability, longer in shelf life, insensitive to repeated freeze thawing, low in production cost, stable in synthesis process, different in batch, short in production cycle, free of species limitation and the like, the linear range of C4 detection of the finally constructed C4 detection kit is 0.16-10 micrograms / mL, and the detection limit is 0.077 micrograms / mL. Due to the high specificity of the aptamer, the kit is suitable for detecting multiple biological samples such as serum, cross reaction can be effectively avoided, and specific high-sensitivity C4 detection can be effectively carried out.

The application provides a digoxin microtablet and a preparation method thereof. The digoxin microtablet prepared by the application contains 5-100 micrograms of digoxin per tablet, which can meet the dosage requirements of patients of different ages, realize precise dosage administration, and reduce the risk of drug overdose in clinical application. The digoxin microtablet provided by the application can solve the problem that infants and children have difficulty in swallowing the medicine, thereby improving the medication compliance of infants and children. Compared with conventional tablets, the microtablet has a smaller volume. The digoxin microtablet provided by the application is prepared by optimizing the prescription and process, preparing a digoxin compound by a spray drying and hot melt extrusion technology, obtaining a solid dispersion, and having better content uniformity and dissolution rate, and significantly improving the bioavailability.

The application discloses a method for constructing a Lewy body dementia mouse model and application, and the method comprises the following steps: taking the fontanel point as an origin, determining the stereotactic coordinates of the bilateral NBM of the mouse, and the coordinates are as follows: AP: -0.6 mm, ML: ±2.1 mm, DV: 4.4-4.6 mm; drilling a small hole at the skull position corresponding to the target coordinates, and stereotaxically injecting a suspension of alpha-synuclein PFFs into the bilateral NBM brain regions of the mouse, with the injection volume of each side being 1 microliter and the concentration being 2 micrograms / microliter; and after the injection is completed, the scalp incision is sutured. The application successfully constructs a DLB / PDD animal model which can cover key cognitive brain regions in pathology and stably exhibit cognitive impairment in behavior by precisely injecting PFFs into the bilateral NBM of the mouse.

The invention discloses a targeted retina drug-loaded extracellular vesicle as well as a preparation method and application thereof. The targeted retina drug-loaded extracellular vesicle comprises a lactobacillus-derived extracellular vesicle and a retina ischemia-reperfusion injury related disease treatment drug loaded in the extracellular vesicle, the medicine for treating the diseases related to the retinal ischemia reperfusion injury is indolepropionic acid; the loading capacity of the targeted retina drug-loading extracellular vesicle to indolepropionic acid is (6-8) * 10 <-8 > microgram / particle. The drug-loaded extracellular vesicle has the advantages of high drug loading rate, good biocompatibility, good gastrointestinal tract stability, high bioavailability and good safety. Besides, the extracellular vesicles loaded with indolepropionic acid can carry related marker proteins of retinal neurons through a membrane fusion technology, and can reach an eye retina area more efficiently through peripheral vein administration.

Provided are novel serum-free culture media which comprise basic fibroblast growth factor (bFGF), transforming growth factor beta-3 and ascorbic acid at a concentration of at least about 50 microgram / ml; ascorbic acid at a concentration range of about 400-600 microgram / ml, bFGF at a concentration range of about 50-200 ng / ml, xeno-free serum replacement and a lipid mixture; the IL6RIL6 chimera at a concentration range of about 50-200 picogram per milliliter (pg / ml); or leukemia inhibitory factor (LIF) at a concentration of at least 2000 units / ml; cell cultures comprising same with pluripotent stem cells such as human embryonic stem cells and induced pluripotent stem (iPS) cells, and methods of using same for expanding pluripotent stem cells in an undifferentiated state using two-dimensional or three-dimensional culture systems; and methods of expanding iPS cells in a suspension culture devoid of substrate adherence and cell encapsulation.

The application discloses a heat-resistant uric acid oxidase TCI-UOX2 and application, and relates to the technical field of biology.The amino acid sequence of the heat-resistant uric acid oxidase TCI-UOX2 is shown as SEQ ID NO:1.The recombinant uric acid oxidase TCI-UOX2 shows the highest activity at 35 DEG C and pH 8, and still maintains about 100 percent relative activity at 5 DEG C to 40 DEG C.The enzyme still maintains about 100 percent residual activity after being incubated at the human physiological temperature of 37 DEG C for 12 hours.Under the anticoagulation environment of a high-uric-acid volunteer, the uric acid concentration can be reduced to the normal level of 360 micromoles per liter within 6 hours of reaction with the low-concentration 1 microgram per milliliter TCI-UOX2 enzyme solution.

The present application relates to compositions comprising flumazenil and naltrexone and methods of use thereof. In particular, the present invention relates to a pharmaceutical composition comprising a microdose of flumazenil and a microdose of naltrexone, or a pharmaceutically acceptable salt thereof, where the flumazenil and naltrexone are present in a weight ratio of about 25: 1 to about 10: 1, where the composition is in the form of a single dose unit, and wherein the single dose unit comprises flumazenil in an amount that provides a daily microdose in the range of about 250 to about 7,500 micrograms and naltrexone in an amount that provides a daily microdose in the range of about 25 to about 1,000 micrograms. The present invention also relates to methods of treating depression and / or anxiety and / or post traumatic stress disorder (PTSD) using a combination of flumazenil and naltrexone.

The present disclosure provides a vaccine composition comprising six or more different antigen components that are homologous. Any two of the six or more homologous different antigen components have a sequence identity of less than 98% or 95%. Different antigen components of homology may comprise proteins. The amount of protein in one dose of the adult vaccine composition may be from about 600 nanograms (ng) to about 3 micrograms ([mu] g). Different antigen components of homology may comprise a variety of RNAs. An amount of one of the plurality of RNAs in a dose of the vaccine composition may be from about 1 ng to about 5 [mu] g per dose. Different antigen components of homology may comprise a plurality of proteins displayed on heterologous virus-like particles (VLPs). In one dose of the vaccine composition, an amount of one protein exhibited on the heterologous VLP of the plurality of proteins exhibited on the heterologous VLP may be from about 1 ng to about 5 [mu] g per dose.

A combination therapy for treating pulmonary hypertension (e.g., PAH, PH-ILD) includes a dose of treprostinil comprising greater than 10 micrograms of treprostinil and a dose of an ActRIIA fusion protein. The dose of treprostinil and the dose of ActRIIA fusion protein may be administered concurrently or sequentially. Further methods for treating pulmonary hypertension include administering a therapeutically effective amount of ActRIIA fusion protein to a subject who has received a composition containing treprostinil, or administering a composition containing treprostinil to a subject who has received a therapeutically effective amount of ActRIIA fusion protein. The treprostinil may be administered as a dry7 powder or liposomal composition.

The present disclosure provides a vaccine composition comprising six or more homologous distinct antigen components. Any two of the six or more homologous distinct antigen components may share less than 98% or 95% sequence identity. The homologous distinct antigen components may comprise proteins. An amount of a protein in a dose of said human adult vaccine composition may be about 600 nanograms (ng) to about 3 micrograms (μg). The homologous distinct antigen components may comprise a plurality of RNA. An amount of an RNA of said plurality of RNA in a dose of said vaccine composition may be about 1 ng to about 5 μg per dose. The homologous distinct antigen components may comprise a plurality of proteins displayed on heterologous viral-like particles (VLPs). An amount of a protein displayed on a heterologous VLP of the plurality of proteins displayed on heterologous VLPs in a dose of the vaccine composition may be about 1 ng to about 5 μg per dose.

The invention discloses a method for efficiently differentiating monkey spermatogonial stem cells in vitro and application. The invention belongs to the technical field of biology, and particularly relates to a method for efficiently differentiating monkey spermatogonial stem cells in vitro and application. The active ingredients of the composition for promoting in-vitro differentiation of the monkey spermatogonial stem cells are retinoic acid, BMP4, testosterone and a basic differentiation medium. The concentration of the retinoic acid in the composition is 1 [mu] mol / L, the concentration of the BMP4 is 50 [mu] g / L, and the concentration of the testosterone is 0.1 mmol / L. According to the method, a culture system for in-vitro differentiation of the monkey spermatogonial stem cells (SSCs) into the functional haploid sperms is successfully established, the haploid differentiation efficiency can be obviously improved (the proportion exceeds 8%) after 96 hours of continuous treatment, and the blank of research on in-vitro differentiation systems and molecular mechanisms of the monkey SSCs is filled.

The invention provides a composition containing neural stem cell exosomes. The composition comprises the neural stem cell exosomes and a carrier compound, wherein the carrier compound comprises hyaluronic acid and phosphatidylserine, and the mass part ratio of the hyaluronic acid to the phosphatidylserine is (1-5): 1; the neural stem cell exosome exists in the carrier compound in a physical compounding manner; in the composition, the content of the neural stem cell exosomes is 0.5-20 micrograms per milligram of carrier compound based on the total amount of the contained protein. The composition is applied to preparation of drugs for treating nerve injury diseases. The bottleneck of application of the neural stem cell exosome in the field of nerve injury treatment is solved, and the treatment effect of the composition can be repeated.